Alexandra Gerlach, Content Producer

FDA-approved colorectal cancer blood tests—Shield, Epi proColon, SimpleScreen—expand blood-based screening, but positives still need colonoscopy.

From isotope decay to patient access, radiopharmaceuticals present unique challenges for oncology pharmacists.

FDA-cleared HPV self-collection kits like Teal Wand expand cervical cancer screening; pharmacists support follow-up, HPV education, and Gardasil.

Case counts will likely continue to rise as reporting catches up with the incubation lag.

Cyclospora cases surge nationwide; learn symptoms, testing pitfalls, treatment, and smart food-water precautions as investigators search for the source.

AML and menin inhibitors transform acute myeloid leukemia treatment: FDA-approved choices, MEN1 protein target, and bedside toxicity monitoring.

Pharmacy streamlines bispecific programs with tailored operations, scheduling, order sets, and reimbursement checkpoints.

Oncology pharmacists step into precision care—tracking mRNA vaccines, frailty-guided supportive therapy, NGS actionability, and new thoracic targets.

New GI cancer data highlight emerging targeted therapies, ctDNA-guided surveillance, and pharmacist-led workflows to boost outcomes.

New breast cancer trial insights reshape metastatic care: Sacituzumab benefits broadly, oral SERDs lag, and denosumab every 12 weeks suffices.

Oncology pharmacists decode 2026 ASCO/EHA breakthroughs, from breast cancer to myeloma, highlighting real-world steps for safer, faster care.

Data presented at the 2026 European Hematology Association Congress continue to support venetoclax plus obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia.

Phase 3 frontMIND phase 3 trial data show tafasitamab plus lenalidomide with R-CHOP boosts PFS and has manageable safety in high-risk newly diagnosed DLBCL.

Vince Sung, PharmD, MBA, BCOP, BCPS, discusses the clinical implications of the updated prostate cancer guidelines.

Darovasertib plus crizotinib boosts survival signals and response rates in HLA-A2–negative metastatic uveal melanoma, with manageable safety.

Results from the SERENA-6 trial show that an early switch to the oral selective estrogen receptor degrader camizestrant combined with a CDK4/6 inhibitor improves progression-free survival 2, delays chemotherapy, and preserves quality of life.

Data presented at ASCO 2026 show giredestrant plus palbociclib extends PFS in ER+/HER2– metastatic breast cancer; FDA approval is on the horizon.

ASCENT-04 updated data show sacituzumab govitecan plus pembrolizumab extends benefit past progression in PD-L1+ metastatic TNBC.

Elizabeth Budde, MD, discusses the phase 3 data behind the mosunetuzumab plus polatuzumab vedotin combination in the SUNMO trial.

ASCO 2026: Daraxonrasib boosts survival and PFS in metastatic pancreatic cancer vs chemotherapy, with better tolerability and quality-of-life preservation.

ASCO 2026 data show encorafenib plus cetuximab with FOLFIRI boosts response and PFS in BRAF V600E mCRC, complementing FOLFOX.

Phase 3 SARC041 data show that abemaciclib sharply extends progression-free survival in advanced dedifferentiated liposarcoma, hinting at a new standard.

The trial met both dual primary end points of pathologic complete response and metastasis-free survival.

SARC041 data shows the clinical benefits associated with abemaciclib in the treatment of patients with incredibly rare diseases.

Apalutamide plus androgen deprivation therapy significantly increased the curative success of radical prostatectomy in patients with localized prostate cancer.

At ASCO 2026, GLORA investigators report on lisaftoclax as an addition to BTK inhibitors to deepen responses and delay progression in high-risk CLL/SLL.

Seven-year CROWN trial update shows lorlatinib delivers durable progression-free survival and strong brain control in ALK-positive NSCLC.

DREAMM-9 data show belantamab mafodotin in TI NDMM delivers high responses, with longer dosing improving eye safety and quality of life.

Enfortumab vedotin combination delivers lasting complete responses in la/mUC.

ASCO 2026 data show perioperative enfortumab vedotin plus pembrolizumab boosts EFS, OS, and pCR in cisplatin-eligible MIBC.